Dr. Gregory Cote, MD
Claim this profileMassachusetts General Hospital
Studies Sarcoma
Studies Solid Tumors
19 reported clinical trials
27 drugs studied
Area of expertise
1Sarcoma
Stage IV
Stage III
archival tumor tissue
2Solid Tumors
Stage IV
Stage III
TAZ-CAMTA1 positive
Affiliated Hospitals
Massachusetts General Hospital
Dana-Farber - Harvard Cancer Center LAO
Clinical Trials Gregory Cote, MD is currently running
Sphincterotomy
for Acute Recurrent Pancreatitis
The purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. People who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will be will be randomly assigned to either have the ERCP with sphincterotomy procedure, or to have a "sham" procedure. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until a maximum follow-up period of 48 months.
Recruiting0 awards N/A7 criteria
INBRX-109
for Chondrosarcoma
This trial tests INBRX-109, a specially designed protein, in patients with a hard-to-treat type of bone cancer. The treatment helps the immune system target and kill cancer cells by attaching to a specific marker on these cells.
Recruiting0 awards Phase 26 criteria
More about Gregory Cote, MD
Clinical Trial Related6 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Gregory Cote, MD has experience with
- Nivolumab
- Lurbinectedin
- Ipilimumab
- Irinotecan
- TP-1287
- IK-930
Breakdown of trials Gregory Cote, MD has run
Sarcoma
Solid Tumors
Tumors
Soft Tissue Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory Cote, MD specialize in?
Gregory Cote, MD focuses on Sarcoma and Solid Tumors. In particular, much of their work with Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Gregory Cote, MD currently recruiting for clinical trials?
Yes, Gregory Cote, MD is currently recruiting for 9 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Gregory Cote, MD has studied deeply?
Yes, Gregory Cote, MD has studied treatments such as Nivolumab, Lurbinectedin, Ipilimumab.
What is the best way to schedule an appointment with Gregory Cote, MD?
Apply for one of the trials that Gregory Cote, MD is conducting.
What is the office address of Gregory Cote, MD?
The office of Gregory Cote, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02114 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.